Phase II study for patients with mesothelioma begin

Drug discovery and development of companies Bionomics Australia intends to start a Phase II clinical trial discontinued with the agent BNC105 in patients with mesothelioma.

Mesothelioma is a rare form of cancer caused mainly by natural asbestos minerals. Most people diagnosed with mesothelioma were first being exposed to asbestos through the manipulation of materials containing asbestos in the use of toxic minerals was a common practice.

Today, many states strict rules on the use of asbestos in products. In addition to a high rate in Australia, malignant mesothelioma affects approximately 2000-3000 people in the United States each year.

The phase II BNC105 is a study of patients with mesothelioma who have experienced progression after chemotherapy with platinum pemetrexed.
While trying to BNC105 the patients in the first days and eight cycles are administered 21 days. The treatment is continued until tumor progression evident.

According to Deborah Rathjen, CEO and Chairman of Bionomics, should the provisional results of the study in early 2011 will be available.

Additional information can be found on mesothelioma, even if the center of mesothelioma.